Thank you for applying for mAbs at Home Treatment. Someone from our team will reach out to you for the next step in the process.
Please note that mAbs At Home provides monoclonal antibody treatments utilizing several types of FDA authorized monoclonals. Circulating SARS-CoV-2 viral variants, including Omicron, may be associated with resistance to monoclonal antibodies. The frequency of the Omicron variant is increasing throughout the U.S. Data shows that it is unlikely that Eli Lilly’s bamlanivimab and etesevimab or Regenron’s REGEN-COV will retain activity against this variant. GSK’s Sotrovimab appears to retain activity against the Omicron variant. Mabs At Home is currently following guidance by reserving GSK’s Sotrovimab for only the highest-risk patients.
